O. WHITMORE BURTNER, M.D.; LOUIS C. JENSEN, M.D.; JOHN M. RUMBALL, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
The usefulness of nitrogen mustard (HN2) in the palliative treatment of certain lymphomas has become well established since the original trials in 1942.1 More recently, a nitrogen mustard-like preparation, triethylene melamine (TEM) has been found to have therapeutic effects somewhat similar to those of nitrogen mustard itself. This new compound possesses the practical advantages, as contrasted with nitrogen mustard, of being effective by mouth, producing less nausea and little or no vomiting, obviating the necessity of hospitalization during treatment and providing a compound with prolonged effect well suited to spaced maintenance therapy.
The structural formula of triethylene melamine, chemically 2,
BURTNER OW, JENSEN LC, RUMBALL JM. TRIETHYLENE MELAMINE IN THE TREATMENT OF LYMPHOMAS AND OTHER NEOPLASTIC DISEASES*. Ann Intern Med. 1953;38:1222–1244. doi: https://doi.org/10.7326/0003-4819-38-6-1222
Download citation file:
Published: Ann Intern Med. 1953;38(6):1222-1244.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use